SCHEMBL20249248

SCHEMBL20249248

CC(C)(C)c1ccc(N2CC3(CCNC3)C2)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.41
ALDH1A1 P00352 11/20 0.40
HSD17B10 Q99714 8/20 0.40
CYP2D6 P10635 8/20 0.40
CYP1A2 P05177 7/20 0.40
CYP3A4 P08684 7/20 0.40
HPGD P15428 6/20 0.40
USP2 O75604 6/20 0.40
TP53 P04637 4/20 0.40
MAPK1 P28482 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CDK4 P11802 1/20 0.37
CCND1 P24385 1/20 0.37
CDK6 Q00534 1/20 0.37
PTPN11 Q06124 1/20 0.36
KHK P50053 1/20 0.35
CYP2C19 P33261 4/20 0.35
CYP2C9 P11712 2/20 0.35
PIM1 P11309 1/20 0.35
PIM3 Q86V86 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20249246 0.92 ALDH1A1 (0.45) TSHRALDH1A1HSD17B10CYP2D6CYP1A2
SCHEMBL20249244 0.92 TSHR (0.50) TSHRALDH1A1HSD17B10CYP2D6CYP1A2
SCHEMBL20249243 0.89 CDK4 (0.40) TSHRALDH1A1HSD17B10CYP2D6CYP1A2
SCHEMBL18291591 0.82 TSHR (0.44) TSHRALDH1A1HSD17B10CYP2D6CYP1A2
SCHEMBL20249239 0.81 CYP3A4 (0.33) TSHRALDH1A1HSD17B10CYP2D6CYP1A2
SCHEMBL18291277 0.79 TSHR (0.44) TSHRALDH1A1HSD17B10CYP2D6CYP1A2
SCHEMBL20249245 0.79 CHRNB2 (0.51) CDK4CCND1CHRNB2CHRNB4CHRNA3
SCHEMBL20255364 0.79 TSHR (0.44) TSHRALDH1A1HSD17B10CYP2D6CYP1A2
SCHEMBL12758913 0.79 TSHR (0.44) TSHRALDH1A1HSD17B10CYP2D6CYP1A2
Hydrochloric Acid SCHEMBL30327720 0.78 CYP3A4 (0.44) TSHRALDH1A1HSD17B10CYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 TSHR 2977/4885ALDH1A1 944/4885HSD17B10 2513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.